Portal de Periódicos da CAPES

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

2007; Ferrata Storti Foundation; Volume: 92; Issue: 9 Linguagem: Inglês

10.3324/haematol.11329

1592-8721

Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, F Mandelli, Francesco Lo‐Coco,

Cancer therapeutics and mechanisms

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.